Spyre Therapeutics Inc SYRE

Healthcare Biotechnology

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

NDAQ:SYRE - Post by User

Spyre Therapeutics Inc

<< Previous

Bullboard Posts

Post by whytestockson Dec 04, 2024 12:47pm

13 Views

Post# 36345460

Bronstein, Gewirtz & Grossman, LLC Announces an Investigatio

BREAKING NEWS: $SYRE Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the InvestigationNEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional infor...SYRE - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

<< Previous

Bullboard Posts

Thunder Gold makes generational discovery